Oliceridine is under clinical development by Trevena and currently in Phase II for Pain. According to GlobalData, Phase II drugs for Pain have a 46% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Oliceridine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Oliceridine (Olinvyk) is an opioid agonist. It is formulated as solution for intravenous route of administration. Olinvyk is indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate.
Oliceridine (TRV-130) is under development for the treatment of moderate to severe acute post-operative pain in hallux valgus (Bunion). It is a small molecule administered through intravenous bolus injection. The drug candidate is a new chemical entity (NCE). It targets the mu-opioid receptor. The drug candidate is developed based on Advanced Biased Ligand Explorer (ABLE) platform.
Trevena is a biotechnology company. It discovers and develops G-protein coupled receptor targeted medicines. The company provides products such as RV045, TRV734 and TRV250. Its TRV045 is an oral drug used for the treatment of acute and chronic neuropathic pain secondary to diabetic peripheral neuropathy. Trevena’s TRV734 is also an oral drug which is used in medication- assisted therapy for the treatment of opioid use disorder. The company’s GPCR is associated with beneficial versus adverse biological effects. Its TRV250 is an oral delta opioid biased ligand for treatment of refactory migraine. Trevena is headquartered in Chesterbrook, Pennsylvania, the US.
For a complete picture of Oliceridine’s drug-specific PTSR and LoA scores, buy the report here.